On March 3, 2025, Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma Corporation initiated five international lawsuits against Moderna, Inc. and its affiliates. These enforcement actions target alleged infringing activities in 30 countries, seeking monetary relief and injunctions against Moderna's Spikevax and mRESVIA products.
The lawsuits allege infringement of key patents related to lipid nanoparticle (LNP) technology, which is crucial for delivering mRNA molecules to human cells. Genevant and Arbutus submitted evidence from testing commercial Moderna product samples, indicating they fall under the protective scope of their lipid composition patents. This expands on an ongoing U.S. District Court case against Moderna, where a jury trial is scheduled for September 2025.
This legal action represents a significant potential value driver for Roivant, given the widespread use of LNP technology in mRNA vaccines. A favorable outcome could result in substantial damages and royalties, impacting Roivant's financial outlook. The litigation highlights the importance of intellectual property in the biopharmaceutical industry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.